Gene therapy manufacturing is undergoing critical scaling to meet rising patient demand, especially for polygenic diseases like Parkinson’s. Industry standard 200-liter bioreactors are proving insufficient, pushing developers towards 1,000-liter or larger vessels. A significant bottleneck exists in the stability of transfection complexes, which must be added within minutes to prevent aggregation and loss of efficiency. This poses technical challenges in delivering large volumes rapidly and intact, as detailed by Fletcher Malcom of Mirus Bio LLC. These manufacturing limitations directly impact the commercial viability and accessibility of viral gene therapies moving forward.